Αποτελέσματα Αναζήτησης
24 Ιουλ 2024 · Cisgender women account for approximately half the 1.3 million new human immunodeficiency virus (HIV) infections that occur worldwide each year. 1 The first HIV preexposure prophylaxis...
24 Ιουλ 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
24 Ιουλ 2024 · Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday.
Antiretroviral pre-exposure prophylaxis is highly effective in preventing HIV infection in women at risk of HIV-1 infection. Cabotegravir is superior to oral tenofovir disoproxil fumarate plus emtricitabine and might overcome many of the challenges of daily oral PrEP in women.
3 Οκτ 2024 · A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.
24 Ιουν 2024 · MONDAY, June 24, 2024 -- Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show. In announcing the findings, Gilead Sciences Inc. said its HIV medication lenacapavir demonstrated 100% efficacy as a preventive treatment.
